Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.770 +0.350 (+24.65%)
Streaming Delayed Price Updated: 2:35 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
Via Benzinga
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
From Aldeyra Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Aldeyra Therapeutics: Q1 Earnings Insights
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday. 
Via Benzinga
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
How To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call
Aldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Aldeyra Therapeutics Announces Chief Financial Officer Transition
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics: Q4 Earnings Insights
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Aldeyra Therapeutics Q4 Earnings
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc
Via Business Wire
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
Aldeyra Therapeutics Earnings Preview
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.... 
Via Benzinga
Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
From Aldeyra Therapeutics
Via Business Wire
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.